OBJECTIVE: This randomized clinical study examined the use of hyaluronic acid to treat infrabony periodontal defects over a period of 24 months. METHOD AND MATERIALS: Forty subjects with a two-wall infrabony defect (probing depth [PD] >= 7 mm; clinical attachment level [CAL] >= 7 mm) were selected. The defects were randomly divided into two groups: sites treated with hyaluronic acid (test group) and those treated with open flap debridement (control group). RESULTS: The 12- and 24-month evaluations were based on clinical and radiographic parameters. The primary outcome variable was CAL. Test defects shows a mean CAL gain of 1.9 ± 1.8 mm, while the control defects yielded a significantly lower gain of 1.1 ± 0.7 mm. PD reduction was also significantly higher in the test group (1.6 ± 1.2 mm) than in the control group (0.8 ± 0.5 mm). Frequency distribution analysis of the study outcomes indicated that hyaluronic acid increased the predictability of clinically significant results (CAL gains >= 2 mm and PD reduction >= 2 mm) in the test group compared with the controls. CONCLUSIONS: The treatment of infrabony defects with hyaluronic acid offered an additional benefit in terms of CAL gain, PD reduction, and predictability compared to treatment with open flap debridement.
RCT Entities:
OBJECTIVE: This randomized clinical study examined the use of hyaluronic acid to treat infrabony periodontal defects over a period of 24 months. METHOD AND MATERIALS: Forty subjects with a two-wall infrabony defect (probing depth [PD] >= 7 mm; clinical attachment level [CAL] >= 7 mm) were selected. The defects were randomly divided into two groups: sites treated with hyaluronic acid (test group) and those treated with open flap debridement (control group). RESULTS: The 12- and 24-month evaluations were based on clinical and radiographic parameters. The primary outcome variable was CAL. Test defects shows a mean CAL gain of 1.9 ± 1.8 mm, while the control defects yielded a significantly lower gain of 1.1 ± 0.7 mm. PD reduction was also significantly higher in the test group (1.6 ± 1.2 mm) than in the control group (0.8 ± 0.5 mm). Frequency distribution analysis of the study outcomes indicated that hyaluronic acid increased the predictability of clinically significant results (CAL gains >= 2 mm and PD reduction >= 2 mm) in the test group compared with the controls. CONCLUSIONS: The treatment of infrabony defects with hyaluronic acid offered an additional benefit in terms of CAL gain, PD reduction, and predictability compared to treatment with open flap debridement.
Authors: Alefiya S Mamajiwala; Kunal S Sethi; Chetan P Raut; Prerna A Karde; Batul S Mamajiwala Journal: Clin Oral Investig Date: 2021-02-17 Impact factor: 3.573
Authors: Manuele Casale; Antonio Moffa; Paola Vella; Lorenzo Sabatino; Francesco Capuano; Beatrice Salvinelli; Michele Antonio Lopez; Francesco Carinci; Fabrizio Salvinelli Journal: Int J Immunopathol Pharmacol Date: 2016-06-08 Impact factor: 3.219
Authors: Masako Fujioka-Kobayashi; Heinz-Dieter Müller; Andrea Mueller; Adrian Lussi; Anton Sculean; Patrick R Schmidlin; Richard J Miron Journal: BMC Oral Health Date: 2017-01-16 Impact factor: 2.757
Authors: Omer B Agrali; Selin Yildirim; Hafize O Ozener; Kemal N Köse; Dilek Ozbeyli; Merva Soluk-Tekkesin; Leyla Kuru Journal: Biomed Res Int Date: 2018-06-28 Impact factor: 3.411